News summary

Making SIRT1 and NAD+ Therapies Work in People

Source: Lifespan.io • Published: 15 Oct 2026, 21:00

Summarized by Masters of Longevity from Lifespan.io.

SIRT1-focused review exploring why boosting SIRT1/NAD+ therapies yield mixed results and proposing how to assess SIRT1’s functional responsiveness.

Making SIRT1 and NAD+ Therapies Work in People
Key Takeaways
  • Reviewers define SIRT1 functional reserve as the remaining operational flexibility of SIRT1 responses under defined stress.
  • Total cellular NAD+ measurements can mislead because NAD+ pools and delivery to SIRT1 are spatially and functionally distinct.
  • The same SIRT1 protein or activity level can produce different functional outputs depending on cell type, stress history, and senescence.
Read the full article at Lifespan.io ↗

Continue exploring

Recommended MoL Picks

MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickCan Doctors Be Trained for the Longevity Era?A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.